Literature DB >> 6813801

The survival of patients with nasopharyngeal carcinoma.

M M Hsu, S C Huang, T C Lynn, T Hsieh, S M Tu.   

Abstract

The survival rates following treatment of 1,555 consecutive, previously untreated patients with nasopharyngeal carcinoma were studied. A 92.5% follow-up rate in 11 years is reported. Overall survival rates were 82.7% at one year, 67.4% at two years, 47.8% at five years, and 39.8% at ten years. Computer analysis revealed various factors influencing the survivals and hence prognosis. The outcomes in this series revealed five categories; clinical staging of nasopharyngeal carcinoma in five stages is, therefore, suggested.

Entities:  

Mesh:

Year:  1982        PMID: 6813801

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

1.  Management of unresectable malignant tumors at the skull base using concomitant chemotherapy and radiotherapy with accelerated fractionation.

Authors:  L B Harrison; D G Pfister; D Kraus; J G Armstrong; M J Zelefsky; J Wiseberg; G J Bosl; E W Strong; J P Shah
Journal:  Skull Base Surg       Date:  1994

2.  Carcinoma of the nasopharynx--comparison of the UICC and Ho clinical staging systems.

Authors:  S L Roth; G Bertram; H Sack
Journal:  Klin Wochenschr       Date:  1989-01-20

3.  Prognostic value of tumor volume in nasopharyngeal carcinoma.

Authors:  Jeong-Hyun Kim; Joon-Kyoo Lee
Journal:  Yonsei Med J       Date:  2005-04-30       Impact factor: 2.759

4.  Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation.

Authors:  Marlinda Adham; Antonius N Kurniawan; Arina Ika Muhtadi; Averdi Roezin; Bambang Hermani; Soehartati Gondhowiardjo; I Bing Tan; Jaap M Middeldorp
Journal:  Chin J Cancer       Date:  2012-02-07

Review 5.  Estimating the global burden of Epstein-Barr virus-related cancers.

Authors:  Yide Wong; Michael T Meehan; Scott R Burrows; Denise L Doolan; John J Miles
Journal:  J Cancer Res Clin Oncol       Date:  2021-10-27       Impact factor: 4.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.